China Medical University Hospital
cmuh.org.twTotal trials
458
Active
86
Phase 3
13
Total enrollment
819,277
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone and N-acetylcysteine | — | — | — | — | — | 1 | |
| NMDAE | — | — | — | — | — | 7 | |
| NMDAE plus Placebo Cap | — | — | — | — | — | 3 | |
| NMDAE plus AIFA | — | — | — | — | — | 2 | |
| Alectinib | — | — | — | — | 2 | ||
| S-1 | — | — | — | — | — | 1 | |
| Nintedanib, gefitinib, erlotinib, afatinib, osimertinib | — | — | — | — | — | 1 | |
| Sertraline | — | — | — | — | — | 1 | |
| Drug: B10 L-BPA | — | — | — | — | — | 1 | |
| B10 L-BPA | — | — | — | — | — | 1 | |
| S1RA plus NMDAE | — | — | — | — | — | 1 | |
| S1RA plus Placebo Cap | — | — | — | — | — | 1 | |
| ADSC01 | — | — | — | — | — | 1 | |
| NMDAE plus AO | — | — | — | — | — | 1 | |
| Imatinib | — | — | — | — | — | 1 | |
| Trametinib | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 2 | ||
| all trans retinoic acid | — | — | — | — | — | 1 | |
| Methylene Blue | — | — | — | — | — | 1 | |
| Omega-3 fatty acids | — | — | — | — | — | 1 | |
| 0.01% concentration atropine drops | — | — | — | — | — | 1 | |
| 0.025% atropine eye drops | — | — | — | — | — | 1 | |
| Traditional Chinese Medicine treatment | — | — | — | — | — | 1 | |
| Blood Biomarker Sampling | — | — | — | — | — | 1 | |
| steroid therapy | — | — | — | — | — | 1 | |
| Dinalbuphine sebacate | — | — | — | — | — | 1 | |
| Analgesic injectables | — | — | — | — | — | 1 | |
| Enteral analgesics | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 |
Next readouts
- 2025-02-28
- 2026-03-02
- 2026-05-20
- 2026-05-31
- 2026-06
- 2026-08-27
- 2026-08-31
- 2026-10
- 2026-10-30
- 2026-11
Top conditions
- Stroke11
- Schizophrenia11
- Breast Cancer9
- Acupuncture8
- Knee Osteoarthritis7
- Healthy6
- Ischemic Stroke6
- Major Depressive Disorder6
Frequently asked questions about China Medical University Hospital
- How many clinical trials does China Medical University Hospital have on ClinicalTrials.gov?
- China Medical University Hospital is listed as the lead sponsor on 458 clinical trials in ClinicalTrials.gov, 86 of which are currently active (recruiting, enrolling, or ongoing).
- How many of China Medical University Hospital's trials are in Phase 3?
- 13 of China Medical University Hospital's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does China Medical University Hospital focus on?
- China Medical University Hospital's most-studied conditions on ClinicalTrials.gov are Stroke, Schizophrenia, Breast Cancer, Acupuncture, Knee Osteoarthritis.
- When are China Medical University Hospital's next clinical trial readouts?
- China Medical University Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer”, expected around 2025-02-28.